Id: acc0593
Group: 1sens
Protein: MDM2
Gene Symbol: MDM2
Protein Id: Q00987
Protein Name: MDM2_HUMAN
PTM: phosphorylation
Site: unclear
Site Sequence:
Disease Category: Cancer
Disease: Pancreas Cancer
Disease Subtype:
Disease Cellline: SW1990
Disease Info:
Drug: sodium cantharidinate
Drug Info: "Sodium cantharidinate is a semi-synthetic derivative of cantharidin, primarily used as an antitumor agent in the treatment of hepatocellular carcinoma, with reduced toxicity compared to its parent compound."
Effect: modulate
Effect Info: "Sodium ftibamzone can reduce the phosphorylation level of MDM2 and simultaneously increase the level of phosphorylated p53, thereby inducing apoptosis of pancreatic cancer cells."
Note:
Score: 4.0
Pubmed(PMID): 33165811
Sentence Index:
Sentence:

Sequence & Structure:

MCNTNMSVPTDGAVTTSQIPASEQETLVRPKPLLLKLLKSVGAQKDTYTMKEVLFYLGQYIMTKRLYDEKQQHIVYCSNDLLGDLFGVPSFSVKEHRKIYTMIYRNLVVVNQQESSDSGTSVSENRCHLEGGSDQKDLVQELQEEKPSSSHLVSRPSTSSRRRAISETEENSDELSGERQRKRHKSDSISLSFDESLALCVIREICCERSSSSESTGTPSNPDLDAGVSEHSGDWLDQDSVSDQFSVEFEVESLDSEDYSLSEEGQELSDEDDEVYQVTVYQAGESDTDSFEEDPEISLADYWKCTSCNEMNPPLPSHCNRCWALRENWLPEDKGKDKGEISEKAKLENSTQAEEGFDVPDCKKTIVNDSRESCVEENDDKITQASQSQESEDYSQPSTSSSIIYSSQEDVKEFEREETQDKEESVESSLPLNAIEPCVICQGRPKNGCIVHGKTGHLMACFTCAKKLKKRNKPCPVCRQPIQMIVLTYFP

Select PDB:

Known Drugs:

source: Multi-Sources

(see table)

Target Drug name MOA Phase Status Disease Source
MDM2 IDASANUTLIN Tumour suppressor p53/oncoprotein Mdm2 inhibitor 3 Terminated acute myeloid leukemia ClinicalTrials
MDM2 NAVTEMADLIN Tumour suppressor p53/oncoprotein Mdm2 inhibitor 2 Recruiting essential thrombocythemia ClinicalTrials
MDM2 SIREMADLIN Tumour suppressor p53/oncoprotein Mdm2 inhibitor 2 Recruiting neoplasm ClinicalTrials
MDM2 IDASANUTLIN Tumour suppressor p53/oncoprotein Mdm2 inhibitor 2 Recruiting neoplasm ClinicalTrials
MDM2 NAVTEMADLIN Tumour suppressor p53/oncoprotein Mdm2 inhibitor 2 Terminated small cell lung carcinoma ClinicalTrials
MDM2 NAVTEMADLIN Tumour suppressor p53/oncoprotein Mdm2 inhibitor 2 Recruiting primary myelofibrosis ClinicalTrials
MDM2 IDASANUTLIN Tumour suppressor p53/oncoprotein Mdm2 inhibitor 2 Terminated polycythemia vera ClinicalTrials
MDM2 NAVTEMADLIN Tumour suppressor p53/oncoprotein Mdm2 inhibitor 2 Active, not recruiting polycythemia vera ClinicalTrials
MDM2 NAVTEMADLIN Tumour suppressor p53/oncoprotein Mdm2 inhibitor 2 Recruiting polycythemia vera ClinicalTrials
MDM2 APG115 Tumour suppressor p53/oncoprotein Mdm2 inhibitor 2 Recruiting lymphoid leukemia ClinicalTrials
MDM2 NAVTEMADLIN Tumour suppressor p53/oncoprotein Mdm2 inhibitor 2 Recruiting endometrial cancer ClinicalTrials
MDM2 NAVTEMADLIN Tumour suppressor p53/oncoprotein Mdm2 inhibitor 1 Completed acute myeloid leukemia ClinicalTrials
MDM2 NAVTEMADLIN Tumour suppressor p53/oncoprotein Mdm2 inhibitor 1 Terminated acute myeloid leukemia ClinicalTrials
MDM2 SIREMADLIN Tumour suppressor p53/oncoprotein Mdm2 inhibitor 1 Terminated acute myeloid leukemia ClinicalTrials
ClinicalTrials
MDM2 SIREMADLIN Tumour suppressor p53/oncoprotein Mdm2 inhibitor 1 Withdrawn acute myeloid leukemia ClinicalTrials
MDM2 APG115 Tumour suppressor p53/oncoprotein Mdm2 inhibitor 1 Recruiting myelodysplastic syndrome ClinicalTrials
MDM2 IDASANUTLIN Tumour suppressor p53/oncoprotein Mdm2 inhibitor 1 Completed acute myeloid leukemia ClinicalTrials
ClinicalTrials
MDM2 NAVTEMADLIN Tumour suppressor p53/oncoprotein Mdm2 inhibitor 1 Active, not recruiting acute myeloid leukemia ClinicalTrials
ClinicalTrials
MDM2 NAVTEMADLIN Tumour suppressor p53/oncoprotein Mdm2 inhibitor 1 Recruiting acute myeloid leukemia ClinicalTrials
MDM2 SIREMADLIN Tumour suppressor p53/oncoprotein Mdm2 inhibitor 1 Completed acute myeloid leukemia ClinicalTrials
MDM2 APG115 Tumour suppressor p53/oncoprotein Mdm2 inhibitor 1 Recruiting acute myeloid leukemia ClinicalTrials
MDM2 IDASANUTLIN Tumour suppressor p53/oncoprotein Mdm2 inhibitor 1 Terminated acute myeloid leukemia ClinicalTrials
MDM2 NAVTEMADLIN Tumour suppressor p53/oncoprotein Mdm2 inhibitor 1 Recruiting chronic myelogenous leukemia ClinicalTrials
MDM2 IDASANUTLIN Tumour suppressor p53/oncoprotein Mdm2 inhibitor 1 Terminated diffuse large B-cell lymphoma ClinicalTrials
MDM2 APG115 Tumour suppressor p53/oncoprotein Mdm2 inhibitor 1 Recruiting liposarcoma ClinicalTrials

Note: Only show clinically investigational or approved drugs with protein targets.

Protein Tractability:

source: Open Targets
Small molecule
Antibody
PROTAC
Other modalities
Approved Drug
Advanced Clinical
Phase 1 Clinical
Structure with Ligand
High-Quality Ligand
High-Quality Pocket
Med-Quality Pocket
Druggable Family
Approved Drug
Advanced Clinical
Phase 1 Clinical
UniProt loc high conf
GO CC high conf
UniProt loc med conf
UniProt SigP or TMHMM
GO CC med conf
Human Protein Atlas loc
Approved Drug
Advanced Clinical
Phase 1 Clinical
Literature
UniProt Ubiquitination
Database Ubiquitination
Half-life Data
Small Molecule Binder
Approved Drug
Advanced Clinical
Phase 1 Clinical

PTM Intensity:

source: CPTAC

No data.

PTM-Disease Association:

source: PTMD
Residue Position State Disease Class PMID
- - U Breast cancer Phosphorylation 35371302

State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.

PTM-Drug Perturbation Response:

source: DecryptM

No data.

Function score:

source: funscoR

No data.

Cross Links: